Solid Tumors Clinical Trial
Official title:
Phase I Study of a Combination of Doxil, Velcade, and Gemcitabine in Advanced Cancer
The goal of this clinical research study is to find the highest safe dose of the drug Velcade (bortezomib) that can be given together with gemcitabine and pegylated liposomal doxorubicin (Doxil) in the treatment of advanced cancer. The effect of this combination treatment on tumor growth will also be studied.
Pegylated liposomal doxorubicin is a newer form of the common anticancer drug Adriamycin. It
is enclosed in liposomes, which are fat particles found normally in the body. This new form
is designed to act against cancer cells while causing less damage to normal tissue.
Gemcitabine is a drug that has shown to be active in patients with several different cancers
including pancreatic cancer, breast cancer, and certain lymphomas. Bortezomib is a new drug
that is designed to block the proteins needed for tumor growth.
Groups of 3 participants that are less than 65 years old and 3-6 participants that are at
least 65 years old will be enrolled at a time. Each new group will receive a higher dose
level than the group before as long as no serious side effects occur.
Once the highest tolerable dose is determined, up to 30 additional patients with small cell
cancer or neuroendocrine carcinoma, and up to 30 patients with T cell lymphoma will be
treated at that dose.
All participants will receive pegylated liposomal doxorubicin through a vein over about 2
hours. The drug will be given once every 21 days (3 weeks or 1 cycle). Gemcitabine will be
given through a vein over 30 minutes on Days 1 and 8 every 21 days. Patients will only
receive the combination of both drugs on Day 1; on that day pegylated liposomal doxorubicin
will be given before the dose of gemcitabine. Bortezomib will be given by vein on Days 1, 4,
8 and 11 of every 21 days, except for the first group of patients who will receive it on
days 1 and 8 only. Participants whose tumors are responding to treatment may continue
treatment if their doctor approves for as long as they respond, as long as there are no
serious side effects.
Because of a nationwide shortage of pegylated liposomal doxorubicin, you may continue
treatment with gemcitabine and bortezomib. If pegylated liposomal doxorubicin becomes
available, you may be able to receive it again.
During the study, you will have a weekly blood test (about 2 tablespoons of blood) and a
physical exam. X-rays and other scans, such as MRIs and CT scans, will be done at 6 weeks to
measure the size of the tumor. Other tests will be done if needed.
The treatment will be stopped if the cancer grows or if severe side effects occur, and other
treatments may be offered.
This is an investigational study. All three drugs are approved by the FDA for use against
some kinds of cancer. Their use in this study is investigational. Up to 276 patients will
take part in this study. All will be enrolled at MD Anderson.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
| Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
| Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
| Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
| Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
| Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
| Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
| Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
| Withdrawn |
NCT01940601 -
Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
|
Phase 2 |